{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-24-002050","form_type":"8-K","ticker":"PHIO","cik":"0001533040","company_name":"Phio Pharmaceuticals Corp.","filed_at":"2024-04-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.872212+00:00","generated_at":"2026-06-04T03:31:38.278110+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Phio Pharmaceuticals reports 2023 net loss of $10.8M; cash at $8.5M with PH-762 trial progress","bullets":["Net loss $10.8M ($5.20/share) vs $11.5M ($10.10/share) in 2022; R&D expenses down 10% to $6.3M.","Cash at Dec 31, 2023: $8.5M, down from $11.8M at end of 2022.","PH-762 Phase 1B: two patients completed treatment with no adverse events; four clinical sites under contract.","Headcount reduced 36% and Marlborough lease not renewed; moved to 321 sq ft lab in Worcester.","AgonOx study delayed; facility renovation expected to reopen May 2024; third patient infused in Nov 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-24-002050","json":"https://secwatch.observer/filing/0001683168-24-002050.json","markdown":"https://secwatch.observer/filing/0001683168-24-002050.md","text":"https://secwatch.observer/filing/0001683168-24-002050.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533040/000168316824002050/0001683168-24-002050-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533040/000168316824002050/phio_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T03:31:38.278110+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0da490993d2196f004fa7ce13587c9d93734794d","claim":"Phio Pharmaceuticals Corp. reported the year ended December 31, 2023 results: net income $10.8 million, EPS $5.20 per share.","evidence_excerpt":"Net loss was $10.8 million, or $5.20 per share, for the year ended December 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1533040/000168316824002050/0001683168-24-002050-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Net income","value":"$10.8 million"},{"label":"EPS","value":"$5.20 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}